# A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531

> **NCT01813227** · PHASE2 · COMPLETED · sponsor: **Hackensack Meridian Health** · enrollment: 7 (actual)

## Conditions studied

- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Rituximab
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01813227
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2014-09
- **Final completion:** 2018-10
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01813227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01813227, "A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01813227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*